Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US7097840B2 · kind B2 · utility
149Cited by
45References
44Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 16, 2001 |
| Grant date | Aug 29, 2006 |
| Priority date | — |
| Expiry date | Jan 27, 2023 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anri-ErbB receptor antibody-maytansinoid conjugates.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.